SCHEMBL3493333

SCHEMBL3493333

CC1(C)CCC[C@@]2(C)[C@H]1CC[C@]13C[C@H](CC[C@@H]12)[C@@](C)(O)C3

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.56
F10 P00742 3/20 0.41
PTPN1 P18031 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 1/20 0.39
HSD11B2 P80365 1/20 0.38
IDO1 P14902 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
TSHR P16473 2/20 0.38
CYP2C19 P33261 2/20 0.38
TRPV1 Q8NER1 1/20 0.37
MAPT P10636 1/20 0.37
PTPN2 P17706 1/20 0.35
CDC25B P30305 1/20 0.35
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16335450 1.00 HSD11B1 (0.56) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL16335449 1.00 HSD11B1 (0.56) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL3493335 1.00 HSD11B1 (0.56) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL30111361 1.00 HSD11B1 (0.56) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL3489806 0.85 HSD11B1 (0.79) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL3489808 0.85 HSD11B1 (0.79) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL5043911 0.83 HSD11B1 (0.81) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL5043912 0.83 HSD11B1 (0.81) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL3490504 0.77 HSD11B1 (0.44) HSD11B1F10PTPN1MEN1KMT2A
SCHEMBL13401496 0.77 HSD11B1 (0.44) HSD11B1F10PTPN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120059850-A Daofu azalea essential oil and preparation method and application thereof 四川省农业特色植物研究院 2025-05-30 CN claimed
US-20170055532-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL Emekatech, LLC. (US) 2017-03-02 US claimed
EP-3110253-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL Emekatech, LLC (US) 2017-01-04 EP claimed
WO-2015127311-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL EMEKATECH, LLC (US) 2015-08-27 WO claimed
EP-2155769-B1 TISSUE DEGENERATION PROTECTION UNIV LEUVEN KATH (BE) 2012-06-27 EP claimed
US-20100297722-A1 TRANSGENIC MOSS PRODUCING TERPENOIDS BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) 2010-11-25 US claimed
US-20100099640-A1 TISSUE DEGENERATION PROTECTION GEUNS JOANNES 2010-04-22 US claimed
EP-2155769-A2 TISSUE DEGENERATION PROTECTION Katholieke Universiteit Leuven (BE) 2010-02-24 EP claimed
WO-2008134828-A2 TISSUE DEGENERATION PROTECTION KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-13 WO claimed
CN-120059850-A Daofu azalea essential oil and preparation method and application thereof 四川省农业特色植物研究院 2025-05-30 CN disclosed
US-20200093135-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL EMEKATECH LLC (US) 2020-03-26 US disclosed
US-10053703-B2 Heterologous production of patchoulol, β-santalene, and sclareol in moss cells UNIVERSITY OF COPENHAGEN (DK) 2018-08-21 US disclosed
US-20170055532-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL Emekatech, LLC. (US) 2017-03-02 US disclosed
EP-3110253-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL Emekatech, LLC (US) 2017-01-04 EP disclosed
WO-2015127311-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL EMEKATECH, LLC (US) 2015-08-27 WO disclosed
EP-2155769-B1 TISSUE DEGENERATION PROTECTION UNIV LEUVEN KATH (BE) 2012-06-27 EP disclosed
US-20100297722-A1 TRANSGENIC MOSS PRODUCING TERPENOIDS BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) 2010-11-25 US disclosed
US-20100099640-A1 TISSUE DEGENERATION PROTECTION GEUNS JOANNES 2010-04-22 US disclosed
EP-2155769-A2 TISSUE DEGENERATION PROTECTION Katholieke Universiteit Leuven (BE) 2010-02-24 EP disclosed
WO-2008134828-A2 TISSUE DEGENERATION PROTECTION KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099640-A1 TISSUE DEGENERATION PROTECTION SORD, CASP3, TXNRD2 HSD11B1 187/4885F10 551/4885PTPN1 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.